Antibe Therapeutics Inc. - CCAA Proceedings

On April 9, 2024, Antibe Therapeutics Inc. ("Antibe" or the "Company"), initiated proceedings (the "CCAA Proceedings") under the Companies Creditors Arrangements Act ("CCAA"). On the same day, the Ontario Superior Court of Justice (the "Court") granted an Initial Order which, among other things: (i) granted a stay of proceedings up to and including April 18, 2024; and (ii) appointed Deloitte Restructuring Inc. as Court-appointed monitor of the business and financial affairs of Antibe (in such capacity, the "Monitor").

On April 22, 2024, the Honourable Justice Osborne issued an endorsement terminating the CCAA Proceedings and confirming the appointment of FTI Consulting Canada Inc. as court-appointed Receiver of Antibe.

Court Orders
CCAA Termination Order  Endorsement	May 13, 2024
Endorsement	April 22, 2024
Endorsement  initial Order	April 9, 2024
Motion Materials
Motion Record - Fee Approval	May 6, 2024
Book of Authorities - Applicant - Antibe  Factum - Applicant Antibe  Factum of the Cross-Applicant - Nuance Pharma Ltd  Reply Record to Cross-Application of Nuance	April 17, 2024
Responding and Cross-Application Record - Respondent - Nuance Pharma Ltd	April 15, 2024
Antibe Motion Record, returnable April 18, 2024	April 12, 2024
Notice of Application	April 9, 2024
Aide Memoire  Application Record	April 8, 2024
Monitor's Reports
First Report of the Monitor (ARIO)	April 15, 2024
Pre-Filing Report	April 8, 2024
Notices and Other Documents
Notice of Appearance  Creditor Listing	April 9, 2024
Service List
Service List	April 17, 2024
Other
Frequently Asked Questions	April 9, 2024